We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medpace (MEDP) Stock Moves -0.36%: What You Should Know
Read MoreHide Full Article
Medpace (MEDP - Free Report) closed at $348.48 in the latest trading session, marking a -0.36% move from the prior day. This move was narrower than the S&P 500's daily loss of 0.39%. Elsewhere, the Dow lost 0.61%, while the tech-heavy Nasdaq lost 0.32%.
Prior to today's trading, shares of the provider of outsourced clinical development services had gained 13.21% over the past month. This has outpaced the Medical sector's loss of 0.78% and the S&P 500's gain of 3.6% in that time.
Market participants will be closely following the financial results of Medpace in its upcoming release. The company is expected to report EPS of $2.97, up 20.73% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $536.37 million, up 7.62% from the prior-year quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $11.93 per share and a revenue of $2.11 billion, signifying shifts of +34.35% and +11.82%, respectively, from the last year.
It is also important to note the recent changes to analyst estimates for Medpace. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. As of now, Medpace holds a Zacks Rank of #3 (Hold).
Looking at its valuation, Medpace is holding a Forward P/E ratio of 29.32. This denotes a premium relative to the industry's average Forward P/E of 16.87.
Also, we should mention that MEDP has a PEG ratio of 1.93. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. By the end of yesterday's trading, the Medical Services industry had an average PEG ratio of 1.52.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 147, which puts it in the bottom 42% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Medpace (MEDP) Stock Moves -0.36%: What You Should Know
Medpace (MEDP - Free Report) closed at $348.48 in the latest trading session, marking a -0.36% move from the prior day. This move was narrower than the S&P 500's daily loss of 0.39%. Elsewhere, the Dow lost 0.61%, while the tech-heavy Nasdaq lost 0.32%.
Prior to today's trading, shares of the provider of outsourced clinical development services had gained 13.21% over the past month. This has outpaced the Medical sector's loss of 0.78% and the S&P 500's gain of 3.6% in that time.
Market participants will be closely following the financial results of Medpace in its upcoming release. The company is expected to report EPS of $2.97, up 20.73% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $536.37 million, up 7.62% from the prior-year quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $11.93 per share and a revenue of $2.11 billion, signifying shifts of +34.35% and +11.82%, respectively, from the last year.
It is also important to note the recent changes to analyst estimates for Medpace. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. As of now, Medpace holds a Zacks Rank of #3 (Hold).
Looking at its valuation, Medpace is holding a Forward P/E ratio of 29.32. This denotes a premium relative to the industry's average Forward P/E of 16.87.
Also, we should mention that MEDP has a PEG ratio of 1.93. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. By the end of yesterday's trading, the Medical Services industry had an average PEG ratio of 1.52.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 147, which puts it in the bottom 42% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.